Form 4: AnaptysBio director reports ESOP share sale

Director John P. Schmid disclosed an indirect sale of 11,068 ANAB shares at $51 via an ESOP and continues to hold 52,267 shares directly.

Summary

• John P. Schmid, a director of AnaptysBio (ANAB), reported an indirect disposition of 11,068 common shares on 2025-12-23.
• The transaction price was $51.00 per share and was coded “J” (other).
• The shares were sold by the SpeakInc. Employee Ownership Plan (“Plan”), for which Schmid serves as a trustee.
• Schmid reports less than 1% pecuniary interest in the Plan and disclaims beneficial ownership beyond that interest.
• Following the reported transaction, indirect ownership via the Plan is shown as 0 shares.
• Schmid reports direct ownership of 52,267 ANAB common shares after the transaction.
• The document was signed by Attorney-in-Fact Eric Loumeau on 2025-12-23.

Sentiment

Score: 5

Explanation: Neutral administrative insider transaction via an ESOP with minimal reported pecuniary interest and no change to the director’s direct holdings.

Positives

• Director maintains a direct stake of 52,267 shares after the transaction.
• The disposition was made by an ESOP for which the director has less than 1% pecuniary interest, limiting alignment concerns.

Negatives

• An insider-related entity (ESOP for which the director is a trustee) sold 11,068 shares at $51, which can be perceived as insider-related selling activity.

Future Outlook

NA

Management Comments

• Shares were sold under the SpeakInc. Employee Ownership Plan (“Plan”), for which the reporting person is a trustee.
• The reporting person has less than 1% pecuniary interest in the Plan and disclaims beneficial ownership beyond that interest.

Industry Context

Routine insider reporting activity; ESOP-related transactions are common administrative movements and typically do not signal strategic shifts in biotech peers.

Comparison to Industry Standards

• The size and nature of the ESOP-related sale are consistent with routine administrative transactions seen at peer biotech companies and do not, by themselves, indicate a change in corporate outlook.
• Maintaining a direct holding (52,267 shares) aligns with common director practices in the sector, comparable to governance norms at mid-cap biotech peers such as Allogene, Arcus, and Geron.

Related Party Transactions

• Sale of 11,068 shares at $51.00 by the SpeakInc. Employee Ownership Plan, where the director serves as a trustee and claims less than 1% pecuniary interest, disclaiming beneficial ownership beyond that interest.

Stakeholder Impact

• Minimal direct impact on shareholders due to the administrative nature of an ESOP sale.
• Director’s ongoing direct ownership of 52,267 shares suggests continued alignment with shareholders.

Key Dates

Keywords

AnaptysBio, ANAB, Form 4, insider transaction, John P. Schmid, common stock, ESOP, beneficial ownership, Rule 16, sale